Bank of America’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
VCM
MCM
TSC
PCM
Bank of America's LUCD Position: Q1 2026 in Review
Bank of America increased its Lucid Diagnostics (LUCD) stake by 26% in Q1 2026, buying an estimated $23.2K and bringing the position to 88,527 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #5512.
Bank of America first reported a position in LUCD in Q4 2021 and has held it in 15 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.
- Bank of America held 88,527 shares of Lucid Diagnostics worth $102K as of Q1 2026.
- Bank of America bought 18,212 Lucid Diagnostics shares in Q1 2026, an estimated $23.2K.
- Lucid Diagnostics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5512 holding.
- Bank of America first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 15 quarters since.
- 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.